1. Pink Sheet
  3. >>Europe

France Takes Aim At Off-Label Use Of GLP-1s Amid Continuing Shortages

 
• By Ian Schofield

A new expert body is examining the use of semaglutide and other GLP-1 receptor agonists, focusing on safety risks and ongoing supply issues.

Demand_Supply_Seesaw
Demand is outstripping supply for Ozempic • Source: Shutterstock

The French medicines regulator ANSM has set up a temporary committee to look into the use of GLP-1 receptor agonists such as Novo Nordisk’s Ozempic (semaglutide) both within and outside their approved indications.

With Ozempic still in short supply amid an increase in its off-label use for weight loss, the committee will be responsible for assessing any safety risks relating to the use of the GLP-1s and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.